Dec. 21, 2016
Invention Description:Discovery of a new family of small molecules that can be used to decrease the risk of thrombosis in patients with several diseases.
Novelty:The most important aspect of this new antithrombotic is that it prevents the transition of platelets to a hypersensitive state without impacting normal hemostatic responses. Current therapies target major platelet activation pathways while our molecule targets a specific pathway only involved in hypersensitivity but not in coagulation. Treating patients with conditions such as systemic lupus erythematosus with this new drug will inhibit platelet hypersensitivity thus preventing thrombosis while maintaining normal hemostasis.
Significant clinical benefit by eliminating bleeding complications and decreasing susceptibility to thrombosis in patients with autoimmune diseases, malignancies and other ailments known to be high risk for thrombosis.
New family of molecules maintains the ability of platelets to respond to thrombotic agents (thrombin, collagen, fibrinogen, ADP) while inhibiting the ability of platelets to become hypersensitive to those thrombotic agents.
Our inhibitor will allow patients susceptible to thrombosis to be treated while maintaining normal hemostasis.
Pre-clinical testing phase.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
systemic lupus erythematosus
maintaining normal hemostasis
inhibit platelet hypersensitivity
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium